The current P/E ratio of SUPN cannot be calculated, as the latest EPS of -$0.29 is negative. The last recorded PE ratio for Supernus Pharmaceuticals was 1447.0 in December 2023.
The average historical PE ratio of Supernus Pharmaceuticals for the last ten years is 71.5. Analyzing the last ten years, SUPN's PE ratio reached its highest point in the Dec 2023 quarter at 1,447, when the price was $28.94 and the EPS was $0.02. The lowest point was recorded in the Mar 2020 quarter, when it reached 8.14 with a price of $17.99 and an EPS of $2.21.
Maximum annual increase: 4,483.47% in 2023
Maximum annual decrease: -70.39% in 2016
| Year | PE ratio | Change |
|---|---|---|
| 2023 | 1,447 | 4,483.47% |
| 2022 | 31.57 | 9.35% |
| 2021 | 28.87 | 176.53% |
| 2020 | 10.44 | -4.92% |
| 2019 | 10.98 | -29.62% |
| 2018 | 15.6 | -55.77% |
| 2017 | 35.27 | 157.07% |
| 2016 | 13.72 | -70.39% |
| 2015 | 46.34 | N/A |
| 2014 | N/A | N/A |
| Stock name | PE ratio | Market cap |
|---|---|---|
| JNJ Johnson & Johnson | 10.55 | $386.7B |
| UTHR UNITED THERAPEUTICS Corp | 15.13 | $15B |
| ABT Abbott Laboratories | 32.58 | $183.08B |
| LLY ELI LILLY & Co | 117.98 | $764.72B |
| BMY Bristol Myers Squibb Co | N/A | $102.27B |
| SUPN Supernus Pharmaceuticals Inc | N/A | $1.69B |
The current price to earnings ratio of SUPN cannot be determined, as its EPS of -$0.29 is negative.
Over the last 3 years, the average PE ratio for SUPN stock is 175.66.
Over the last 5 years, the average PE ratio for SUPN stock is 102.64.
The highest quarterly PE ratio in the last ten years has been 1,447 and it was in the Dec 2023 quarter.
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.